C4 Therapeutics, Inc. (CCCC)

NMS – Real vaqt narxi. Valyuta: USD

4.26

-0.14 (-3.18%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

4.40

+0.14 (3.31%)

Bozordan keyin: Jun 26, 2026, 7:52 PM EDT

$C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population$

11.06.2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status

02.06.2026

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through phase 2 MOMENTUM and phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Strong financial position with $268.3M cash as of March 2026 supports operations into 2028, enabling continued pipeline expansion and clinical execution.

01.06.2026

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

20.05.2026

C4 Therapeutics to Participate in Upcoming Conferences

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.

18.05.2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

15.05.2026

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

12.05.2026

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.37 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

11.06.2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status

18.05.2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12.05.2026

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights.

09.04.2026

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.

C4 Therapeutics, Inc. (CCCC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Search stocks

C4 Therapeutics, Inc. (CCCC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)